前蛋白转化酶枯草溶菌素9抑制剂在ACS早期应用前景  

Application prospect of proprotein convertase subtilisin/kexin type 9inhibitor for acute coronary syndrome

作　　者：邹新亮 景涛 何国祥 ZOU Xinliang;JING Tao;HE Guoxiang(Department of Cardiology,Southwest Hospital,The First Hospital Affiliated to Army Medical University,Chongqing,400000,China)

机构地区：[1]陆军军医大学第一附属医院(西南医院)心血管内科,重庆400000

出　　处：《临床心血管病杂志》2020年第4期378-381,共4页Journal of Clinical Cardiology

摘　　要：急性冠状动脉综合征(ACS)事件早期前蛋白转化酶枯草溶菌素9(PCSK9)水平的动态升高,可促进动脉粥样硬化发展和血栓形成,进而增加未来心血管事件风险。大量研究证据表明PCSK9抑制剂除迅速、强效降低低密度脂蛋白胆固醇作用外,也具有抗炎、稳定斑块、抗血栓等多效性作用。本文就PCSK9在ACS早期进程中的相关作用机制及PCSK9抑制剂的应用前景进行综述。Proprotein Convertase Subtilisin/Kexin type 9(PCSK9)levels have a dynamic increase in acute coronary syndrome(ACS),which promote the process of atherosclerosis(AS)and increase the risk of future cardiovascular events.Strong evidence showed that PCSK9inhibitors reduced the low-density lipoprotein cholesterol(LDL-C)rapidly and strongly,and played anti-inflammatory,plaque stabilizing and anti-thrombolytic pleiotropic activity roles.This review describes the influence and mechanism of PCSK9in the early stage of ACS,as well as the prospect of PCSK9inhibitors for the early application of ACS.

关 键 词：前蛋白转化酶枯草溶菌素9 急性冠状动脉综合征 心肌梗死 动脉粥样硬化 低密度脂蛋白胆固醇 

分 类 号：R541.4[医药卫生—心血管疾病]